US Stock MarketDetailed Quotes

DSNKY Daiichi Sankyo (ADR)

Watchlist
  • 23.020
  • +0.360+1.59%
15min DelayClose Feb 25 16:00 ET
  • 23.020
  • 0.0000.00%
Post 16:22 ET
43.25BMarket Cap26.74P/E (TTM)

About Daiichi Sankyo (ADR) Company

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Company Profile

SymbolDSNKY
Company NameDaiichi Sankyo (ADR)
Founded2005
CEOMr. Sunao Manabe
MarketPink Market
Employees14887
Fiscal Year Ends03-31
AddressDaiichi Sankyo Head Office Bldg, A&B,3-5-1 Nihonbashi-honcho,Chuo-Ku
CityTokyo
ProvinceTokyo
CountryJapan
Zip Code103-8426
Phone81-3-6225-1111

Company Executives

  • Name
  • Position
  • Salary
  • Sunao Manabe
  • Executive Chairman of the Board and Chief Executive Officer
  • --
  • Hiroyuki Okuzawa
  • Director, President and Chief Operating Officer
  • --
  • Takashi Matsumoto
  • Director, Managing Executive Officer, Chief Human Resources Officer and Head of Global HR
  • --
  • Shoji Hirashima
  • Director, Senior Executive Officer and Head, Japan Business Unit
  • --
  • Takashi Fukuoka
  • Director, Senior Executive Officer and Head, Global Corporate Strategy
  • --
  • Kazuaki Kama
  • Chairman of the Board
  • --
  • Yo Honma
  • Independent Director
  • --
  • Takaaki Nishii
  • Independent Director
  • --
  • Yasuhiro Komatsu
  • Independent Director
  • --
  • Sawako Nohara
  • Independent Director
  • --

Trending Stocks

Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.